Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496) Journal Article

Local Library Link: Find It @ Loyola

Authors: Gordon, L. I.; Hong, F.; Fisher, R. I.; Bartlett, N. L.; Connors, J. M.; Gascoyne, R. D.; Wagner, H.; Stiff, P. J.; Cheson, B. D.; Gospodarowicz, M.; Advani, R.; Kahl, B. S.; Friedberg, J. W.; Blum, K. A.; Habermann, T. M.; Tuscano, J. M.; Hoppe, R. T.; Horning, S. J.
Article Title: Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496)
Abstract: PURPOSE: Although ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) has been established as the standard of care in patients with advanced Hodgkin lymphoma, newer regimens have been investigated, which have appeared superior in early phase II studies. Our aim was to determine if failure-free survival was superior in patients treated with the Stanford V regimen compared with ABVD. PATIENTS AND METHODS: The Eastern Cooperative Oncology Group, along with the Cancer and Leukemia Group B, the Southwest Oncology Group, and the Canadian NCIC Clinical Trials Group, conducted this randomized phase III trial in patients with advanced Hodgkin lymphoma. Stratification factors included extent of disease (localized v extensive) and International Prognostic Factors Project Score (0 to 2 v 3 to 7). The primary end point was failure-free survival (FFS), defined as the time from random assignment to progression, relapse, or death, whichever occurred first. Overall survival, a secondary end point, was measured from random assignment to death as a result of any cause. This design provided 87% power to detect a 33% reduction in FFS hazard rate, or a difference in 5-year FFS of 64% versus 74% at two-sided .05 significance level. RESULTS: There was no significant difference in the overall response rate between the two arms, with complete remission and clinical complete remission rates of 73% for ABVD and 69% for Stanford V. At a median follow-up of 6.4 years, there was no difference in FFS: 74% for ABVD and 71% for Stanford V at 5 years (P = .32). CONCLUSION: ABVD remains the standard of care for patients with advanced Hodgkin lymphoma.
Journal Title: Journal of Clinical Oncology
Volume: 31
Issue: 6
ISSN: 0732-183X
Publisher: Unknown  
Journal Place: United States
Date Published: 2013
Start Page: 684
End Page: 691
Language: eng
DOI/URL:

10.1200/JCO.2012.43.4803

10.1200/JCO.2012.43.4803
Notes: LR: 20130419; ClinicalTrials.gov/NCT00003389; GR: CA11083/CA/NCI NIH HHS/United States; GR: CA13650/CA/NCI NIH HHS/United States; GR: CA17145/CA/NCI NIH HHS/United States; GR: CA21076/CA/NCI NIH HHS/United States; GR: CA21115/CA/NCI NIH HHS/United States; GR: CA23318/CA/NCI NIH HHS/United States; GR: CA31946/CA/NCI NIH HHS/United States; GR: CA32102/CA/NCI NIH HHS/United States; GR: CA38926/CA/NCI NIH HHS/United States; GR: CA46282/CA/NCI NIH HHS/United States; GR: CA46441/CA/NCI NIH HHS/United States; GR: CA66636/CA/NCI NIH HHS/United States; GR: CA77202/CA/NCI NIH HHS/United States; GR: CA77440/CA/NCI NIH HHS/United States; GR: U10 CA023318/CA/NCI NIH HHS/United States; GR: U10 CA066636/CA/NCI NIH HHS/United States; JID: 8309333; 11056-06-7 (Bleomycin); 23214-92-8 (Doxorubicin); 33419-42-0 (Etoposide); 4342-03-4 (Dacarbazine); 51-75-2 (Mechlorethamine); 53-03-2 (Prednisone); 57-22-7 (Vincristine); 865-21-4 (Vinblastine); CIN: J Clin Oncol. 2013 Feb 20;31(6):660-2. PMID: 23182992; OID: NLM: PMC3574266 [Available on 02/20/14]; PMCR: 2014/02/20 00:00; 2012/11/26 [aheadofprint]; ppublish